|
Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes
Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o... |
|
Diabetic Macular Edema: Employing Inflammatory Markers to Predict Improved Visual Outcomes
Real-world outcomes with intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of patients with diabetic macular edema (DME) do not always replicate those seen in clinical studies. In part, these discrepancies are due to treatment burden, lack of adherence, undertreatment, and incomplete response to anti-VEGF therapies. The identification of several inflammatory cytokines in the aqueous and vitreous humor whose concentrations correlate closely with the severity o... |